Skip to main content

05-06-2024 | Breast Cancer | News

ASCO 2024

Trastuzumab deruxtecan improves progression-free survival in HER2-low and HER2-ultralow metastatic breast cancer Trastuzumab deruxtecan resulted in significantly better progression-free survival compared with chemotherapy of physician's choice in HER2-low metastatic breast cancer. Similar results were seen in patients with HER2-ultralow breast cancer, report researchers from the DESTINY-Breast06 study.

Related topics